NYSE:BHVN

Biohaven Pharmaceutical Stock Forecast, Price & News

$74.40

-1.43 (-1.89 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$73.96

Now: $74.40▼

$76.84

50-Day Range

$64.07

MA: $74.33▼

$86.38

52-Week Range

$34.78

Now: $74.40▼

$100.77

Volume321,000 shs

Average Volume653,690 shs

Market Capitalization$4.62 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.09

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:BHVN

Previous SymbolNASDAQ:BHVN

CUSIPN/A

CIK1689813

Webwww.biohavenpharma.com

Phone203-404-0410

Employees825

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio3.26

Quick Ratio3.17

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.14) per share

Price / Book-531.43

Profitability

EPS (Most Recent Fiscal Year)($10.91)

Net Income$-528,800,000.00

Net MarginsN/A

Return on Equity-1,091.41%

Return on Assets-120.85%

Miscellaneous

Outstanding Shares62,041,000

Market Cap$4.62 billion

Next Earnings Date5/6/2021 (Estimated)

OptionableOptionable

Headlines

December 17th Options Now Available For Biohaven Pharmaceutical Holding (BHVN)
April 14, 2021 | nasdaq.com

Need To Know: Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Insiders Have Been Buying Shares
April 9, 2021 | nasdaq.com

Biohaven Crushes Forecasts; What's Next For Its Blockbuster Hopeful?
April 7, 2021 | finance.yahoo.com

Biohaven Pharmaceutical (NYSE:BHVN) Shares Gap Up to $65.78
April 7, 2021 | americanbankingnews.com

Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
April 7, 2021 | finance.yahoo.com

Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members
April 6, 2021 | finance.yahoo.com

The Biohaven Pharmaceutical Holding (NYSE:BHVN) Share Price Is Up 179% And Shareholders Are Boasting About It
April 2, 2021 | finance.yahoo.com

Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant
March 29, 2021 | finance.yahoo.com

Is BHVN Stock A Buy or Sell?
March 29, 2021 | finance.yahoo.com

Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
March 29, 2021 | finance.yahoo.com

Biohaven Pharmaceutical Still Looks Unattractive Based on Its Charts
March 23, 2021 | finance.yahoo.com

Thursday 3/18 Insider Buying Report: BHVN, ORCL
March 18, 2021 | nasdaq.com

BHVN Crosses Below Key Moving Average Level
March 16, 2021 | nasdaq.com

Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine
March 11, 2021 | finance.yahoo.com

Biohaven Pharmaceutical Holding Company Ltd.(BHVN)
March 10, 2021 | fool.com

Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
March 2, 2021 | finance.yahoo.com

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
March 1, 2021 | finance.yahoo.com

Biohaven Pharmaceutical Holding Company Ltd. 2020 Q4 - Results - Earnings Call Presentation
March 1, 2021 | seekingalpha.com

Recap: Biohaven Pharmaceutical Q4 Earnings
March 1, 2021 | finance.yahoo.com

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates
March 1, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.99 out of 5 stars

Medical Sector

59th out of 2,024 stocks

Pharmaceutical Preparations Industry

25th out of 772 stocks

4.4 Analyst's Opinion

Consensus Rating
Biohaven Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $96.45, Biohaven Pharmaceutical has a forecasted upside of 29.6% from its current price of $74.40.
Amount of Analyst Coverage
Biohaven Pharmaceutical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.4 Community Rank

Outperform Votes
Biohaven Pharmaceutical has received 325 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biohaven Pharmaceutical has received 353 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biohaven Pharmaceutical has received 52.06% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote “Outperform” if you believe BHVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biohaven Pharmaceutical does not currently pay a dividend.
Dividend Growth
Biohaven Pharmaceutical does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biohaven Pharmaceutical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,851,332.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 19.10% of the stock of Biohaven Pharmaceutical is held by insiders.
Percentage Held by Institutions
99.37% of the stock of Biohaven Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Biohaven Pharmaceutical are expected to grow in the coming year, from ($12.38) to ($9.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biohaven Pharmaceutical is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biohaven Pharmaceutical is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$74.40

-1.43 (-1.89 %)

(As of 04/16/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biohaven Pharmaceutical stock.
View analyst ratings for Biohaven Pharmaceutical or view top-rated stocks.

What stocks does MarketBeat like better than Biohaven Pharmaceutical?

Wall Street analysts have given Biohaven Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biohaven Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Biohaven Pharmaceutical.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted its quarterly earnings results on Sunday, February, 28th. The company reported ($3.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.89) by $0.73. The firm had revenue of $35.10 million for the quarter, compared to the consensus estimate of $35.01 million. The company's revenue for the quarter was up 350900.0% on a year-over-year basis. During the same period last year, the business posted ($2.85) EPS.
View Biohaven Pharmaceutical's earnings history.

How has Biohaven Pharmaceutical's stock price been impacted by Coronavirus (COVID-19)?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BHVN shares have increased by 88.5% and is now trading at $74.40.
View which stocks have been most impacted by COVID-19.

What guidance has Biohaven Pharmaceutical issued on next quarter's earnings?

Biohaven Pharmaceutical issued an update on its first quarter 2021 Pre-Market earnings guidance on Wednesday, April, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $43.8-43.8 million, compared to the consensus revenue estimate of $36.41 million.

What price target have analysts set for BHVN?

12 brokers have issued twelve-month price targets for Biohaven Pharmaceutical's stock. Their forecasts range from $41.00 to $120.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $96.45 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:

Dr. Vladimir Coric, CEO, Pres & Director (Age 50, Pay $1.14M)
Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 57, Pay $656.39k)
Ms. Kimberly Gentile, Sr. VP of Clinical Operations (Age 55, Pay $614.09k)
Dr. Elyse Stock M.D., Chief Medical Officer (Age 63, Pay $594.39k)
Mr. William Jones M.B.A., Chief Commercial Officer of Migraine & Common Diseases (Age 57, Pay $1.3M)
Mr. Clifford Bechtold, Chief Operating Officer
Mr. Matthew DeLawder, Director of Accounting
Dr. Charles Conway, Chief Scientific Officer (Age 59)
Ms. Wendy Goss, Exec. Admin. Assistant
Ms. Jenny Strauss M.P.H., Mang. of Medical Information & Communication

Who are some of Biohaven Pharmaceutical's key competitors?

Some companies that are related to Biohaven Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX) and Ultragenyx Pharmaceutical (RARE).
View all of BHVN's competitors.

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Rothschild Investment Corp IL (0.02%), Canton Hathaway LLC (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical.

Which institutional investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., and Canton Hathaway LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Robert Berman, and William A Jones Jr.
View insider buying and selling activity for Biohaven Pharmaceutical or view top insider-selling stocks.

Which institutional investors are buying Biohaven Pharmaceutical stock?

BHVN stock was bought by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric.
View insider buying and selling activity for Biohaven Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $74.40.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $4.62 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 825 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Where are Biohaven Pharmaceutical's headquarters?

Biohaven Pharmaceutical is headquartered at 215 CHURCH STREET, NEW HAVEN CT, 06510.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.

This page was last updated on 4/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here